Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 94

1.

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

Sparano JA, Gray RJ, Ravdin PM, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2019 Jun 20;380(25):2395-2405. doi: 10.1056/NEJMoa1904819. Epub 2019 Jun 3.

PMID:
31157962
2.

Germline Genetic Variants in GATA3 and Breast Cancer Treatment Outcomes in SWOG S8897 Trial and the Pathways Study.

Larsen V, Barlow WE, Yang JJ, Zhu Q, Liu S, Kwan ML, Ergas IJ, Roh JM, Hutchins LF, Kadlubar SA, Albain KS, Rae JM, Yeh IT, Ravdin PM, Martino S, Lyss AP, Osborne CK, Hortobagyi GN, Kushi LH, Hayes DF, Ambrosone CB, Yao S.

Clin Breast Cancer. 2019 Mar 6. pii: S1526-8209(18)30783-3. doi: 10.1016/j.clbc.2019.02.010. [Epub ahead of print]

PMID:
30928413
3.

Communicating Risks of Adjuvant Chemotherapy for Breast Cancer: Getting Beyond the Laundry List.

Brauer ER, Long EF, Melnikow J, Ravdin PM, Ganz PA.

J Oncol Pract. 2019 Feb;15(2):e98-e109. doi: 10.1200/JOP.18.00162. Epub 2018 Dec 14.

PMID:
30550372
4.

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE Jr, Dees EC, Goetz MP, Olson JA Jr, Lively T, Badve SS, Saphner TJ, Wagner LI, Whelan TJ, Ellis MJ, Paik S, Wood WC, Ravdin PM, Keane MM, Gomez Moreno HL, Reddy PS, Goggins TF, Mayer IA, Brufsky AM, Toppmeyer DL, Kaklamani VG, Berenberg JL, Abrams J, Sledge GW Jr.

N Engl J Med. 2018 Jul 12;379(2):111-121. doi: 10.1056/NEJMoa1804710. Epub 2018 Jun 3.

5.

Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.

Engelhardt EG, van den Broek AJ, Linn SC, Wishart GC, Rutgers EJT, van de Velde AO, Smit VTHBM, Voogd AC, Siesling S, Brinkhuis M, Seynaeve C, Westenend PJ, Stiggelbout AM, Tollenaar RAEM, van Leeuwen FE, van 't Veer LJ, Ravdin PM, Pharaoh PDP, Schmidt MK.

Eur J Cancer. 2017 Jun;78:37-44. doi: 10.1016/j.ejca.2017.03.015. Epub 2017 Apr 14.

PMID:
28412587
6.

Epidemiology of GIST in the Era of Histology Codes--Letter.

Lin A, Hsing AW, Ravdin PM.

Cancer Epidemiol Biomarkers Prev. 2015 Jun;24(6):998. doi: 10.1158/1055-9965.EPI-15-0001. No abstract available.

7.

The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase.

Rutgers E, Piccart-Gebhart MJ, Bogaerts J, Delaloge S, Veer LV, Rubio IT, Viale G, Thompson AM, Passalacqua R, Nitz U, Vindevoghel A, Pierga JY, Ravdin PM, Werutsky G, Cardoso F.

Eur J Cancer. 2011 Dec;47(18):2742-9. doi: 10.1016/j.ejca.2011.09.016. Epub 2011 Nov 1.

PMID:
22051734
8.

Cancer and Leukemia Group B Pathology Committee guidelines for tissue microarray construction representing multicenter prospective clinical trial tissues.

Rimm DL, Nielsen TO, Jewell SD, Rohrer DC, Broadwater G, Waldman F, Mitchell KA, Singh B, Tsongalis GJ, Frankel WL, Magliocco AM, Lara JF, Hsi ED, Bleiweiss IJ, Badve SS, Chen B, Ravdin PM, Schilsky RL, Thor A, Berry DA; Cancer and Leukemia Group B Pathology Committee.

J Clin Oncol. 2011 Jun 1;29(16):2282-90. doi: 10.1200/JCO.2010.33.2023. Epub 2011 Apr 25.

9.

Independent prognostic value of screen detection in invasive breast cancer.

Mook S, Van 't Veer LJ, Rutgers EJ, Ravdin PM, van de Velde AO, van Leeuwen FE, Visser O, Schmidt MK.

J Natl Cancer Inst. 2011 Apr 6;103(7):585-97. doi: 10.1093/jnci/djr043. Epub 2011 Feb 24.

PMID:
21350218
10.

Gene polymorphisms in cyclophosphamide metabolism pathway,treatment-related toxicity, and disease-free survival in SWOG 8897 clinical trial for breast cancer.

Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff M, Hortobagyi GN, Hayes DF, Ambrosone CB.

Clin Cancer Res. 2010 Dec 15;16(24):6169-76. doi: 10.1158/1078-0432.CCR-10-0281.

11.

Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.

Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL; WHI Investigators.

JAMA. 2010 Oct 20;304(15):1684-92. doi: 10.1001/jama.2010.1500.

12.
13.

Manganese superoxide dismutase polymorphism, treatment-related toxicity and disease-free survival in SWOG 8897 clinical trial for breast cancer.

Yao S, Barlow WE, Albain KS, Choi JY, Zhao H, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hortobagyi GN, Hayes DF, Ambrosone CB.

Breast Cancer Res Treat. 2010 Nov;124(2):433-9. doi: 10.1007/s10549-010-0840-0. Epub 2010 Mar 23.

14.

Ki67 in breast cancer: prognostic and predictive potential.

Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA.

Lancet Oncol. 2010 Feb;11(2):174-83. doi: 10.1016/S1470-2045(09)70262-1. Review.

PMID:
20152769
15.

Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial.

Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK; Breast Cancer Intergroup of North America.

Lancet. 2009 Dec 19;374(9707):2055-2063. doi: 10.1016/S0140-6736(09)61523-3. Epub 2009 Dec 10.

16.

High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN.

J Clin Oncol. 2009 Dec 1;27(34):5700-6. doi: 10.1200/JCO.2009.23.2025. Epub 2009 Nov 2.

17.

Hormone replacement therapy and the increase in the incidence of invasive lobular cancer.

Ravdin PM.

Breast Dis. 2008-2009;30:3-8. doi: 10.3233/BD-2009-0283. Review.

PMID:
19850989
18.

Calibration and discriminatory accuracy of prognosis calculation for breast cancer with the online Adjuvant! program: a hospital-based retrospective cohort study.

Mook S, Schmidt MK, Rutgers EJ, van de Velde AO, Visser O, Rutgers SM, Armstrong N, van't Veer LJ, Ravdin PM.

Lancet Oncol. 2009 Nov;10(11):1070-6. doi: 10.1016/S1470-2045(09)70254-2. Epub 2009 Oct 2.

PMID:
19801202
19.

Myeloperoxidase genotypes and enhanced efficacy of chemotherapy for early-stage breast cancer in SWOG-8897.

Ambrosone CB, Barlow WE, Reynolds W, Livingston RB, Yeh IT, Choi JY, Davis W, Rae JM, Tang L, Hutchins LR, Ravdin PM, Martino S, Osborne CK, Lyss AP, Hayes DF, Albain KS.

J Clin Oncol. 2009 Oct 20;27(30):4973-9. doi: 10.1200/JCO.2009.21.8669. Epub 2009 Sep 14.

20.

Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial.

Choi JY, Barlow WE, Albain KS, Hong CC, Blanco JG, Livingston RB, Davis W, Rae JM, Yeh IT, Hutchins LF, Ravdin PM, Martino S, Lyss AP, Osborne CK, Abeloff MD, Hayes DF, Ambrosone CB.

Clin Cancer Res. 2009 Aug 15;15(16):5258-66. doi: 10.1158/1078-0432.CCR-09-0685. Epub 2009 Aug 11.

21.

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN.

Oncologist. 2009 Apr;14(4):320-68. doi: 10.1634/theoncologist.2008-0230. Epub 2009 Apr 3. Review.

22.

Breast cancer after use of estrogen plus progestin in postmenopausal women.

Chlebowski RT, Kuller LH, Prentice RL, Stefanick ML, Manson JE, Gass M, Aragaki AK, Ockene JK, Lane DS, Sarto GE, Rajkovic A, Schenken R, Hendrix SL, Ravdin PM, Rohan TE, Yasmeen S, Anderson G; WHI Investigators.

N Engl J Med. 2009 Feb 5;360(6):573-87. doi: 10.1056/NEJMoa0807684.

23.

Sustained lower rates of breast cancer in the United States.

Cronin KA, Ravdin PM, Edwards BK.

Breast Cancer Res Treat. 2009 Sep;117(1):223-4. doi: 10.1007/s10549-008-0226-8. Epub 2008 Nov 1. No abstract available.

PMID:
18979196
24.

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.

Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW Jr, Perez EA, Shulman LN, Martino S, Sparano JA.

J Clin Oncol. 2008 Sep 1;26(25):4063-71. doi: 10.1200/JCO.2007.14.4501. Epub 2008 Aug 4. Erratum in: J Clin Oncol. 2009 Jul 20;27(21):3566.

25.

Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer.

Wang SJ, Fuller CD, Kim JS, Sittig DF, Thomas CR Jr, Ravdin PM.

J Clin Oncol. 2008 May 1;26(13):2112-7. doi: 10.1200/JCO.2007.14.7934. Epub 2008 Mar 31.

PMID:
18378567
26.

Breast cancer trends: a marriage between clinical trial evidence and epidemiology.

Berry DA, Ravdin PM.

J Natl Cancer Inst. 2007 Aug 1;99(15):1139-41. Epub 2007 Jul 24. No abstract available.

PMID:
17652274
27.

The decrease in breast-cancer incidence in 2003 in the United States.

Ravdin PM, Cronin KA, Howlader N, Berg CD, Chlebowski RT, Feuer EJ, Edwards BK, Berry DA.

N Engl J Med. 2007 Apr 19;356(16):1670-4.

28.

Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables.

Ravdin PM, Davis G.

Lung Cancer. 2006 May;52(2):207-12. Epub 2006 Mar 29.

PMID:
16569460
29.

A decision aid to assist in adjuvant therapy choices for breast cancer.

Siminoff LA, Gordon NH, Silverman P, Budd T, Ravdin PM.

Psychooncology. 2006 Nov;15(11):1001-13.

PMID:
16511899
30.
31.

Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer.

Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM.

J Clin Oncol. 2005 Aug 20;23(24):5542-51.

PMID:
16110015
32.
33.

Population-based validation of the prognostic model ADJUVANT! for early breast cancer.

Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA.

J Clin Oncol. 2005 Apr 20;23(12):2716-25.

PMID:
15837986
34.

Managing the risk of osteoporosis in women with a history of early breast cancer.

Ravdin PM.

Oncology (Williston Park). 2004 Oct;18(11):1385-90, 1393; discussion 1394. Review.

35.
36.

A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer.

Lyman GH, Green SJ, Ravdin PM, Geyer CE Jr, Russell CA, Balcerzak SP, Thomas Budd G, Martino S; Southwest Oncology Group Randomized Phase II Study.

Breast Cancer Res Treat. 2004 May;85(2):143-50.

PMID:
15111772
37.
38.

Choosing between endocrine therapy and chemotherapy--or is there a role for combination therapy?

Forbes JF, Gradishar WJ, Ravdin PM.

Breast Cancer Res Treat. 2002 Oct;75 Suppl 1:S37-44; discussion S57-9. Review.

PMID:
12353822
39.

Decision-making in early breast cancer: guidelines and decision tools.

Baum M, Ravdin PM.

Eur J Cancer. 2002 Apr;38(6):745-9.

PMID:
11937306
41.

Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer.

Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL.

J Clin Oncol. 2001 Feb 15;19(4):980-91.

PMID:
11181660
42.

Overview of randomized trials of systemic adjuvant therapy.

Ravdin PM.

Cancer Treat Res. 2000;103:157-81. Review. No abstract available.

PMID:
10948446
43.

A prognostic model that makes quantitative estimates of probability of relapse for breast cancer patients.

De Laurentiis M, De Placido S, Bianco AR, Clark GM, Ravdin PM.

Clin Cancer Res. 1999 Dec;5(12):4133-9.

44.

Should HER2 status be routinely measured for all breast cancer patients?

Ravdin PM.

Semin Oncol. 1999 Aug;26(4 Suppl 12):117-23.

PMID:
10482203
45.

Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.

Ravdin PM.

Semin Oncol. 1999 Jun;26(3 Suppl 9):20-3. Review.

PMID:
10426455
46.

Time-dependence of hazard ratios for prognostic factors in primary breast cancer.

Hilsenbeck SG, Ravdin PM, de Moor CA, Chamness GC, Osborne CK, Clark GM.

Breast Cancer Res Treat. 1998;52(1-3):227-37.

PMID:
10066085
47.

How can prognostic and predictive factors in breast cancer be used in a practical way today?

Ravdin PM.

Recent Results Cancer Res. 1998;152:86-93. Review.

PMID:
9928549
48.

A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer.

Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM, Holmes FA, Rahman Z, Schottstaedt MW, Erban JK, Esparza-Guerra L, Earhart RH, Hortobagyi GN, Burris HA 3rd.

J Clin Oncol. 1998 Oct;16(10):3362-8.

PMID:
9779713
49.

Radiation therapy and survival in breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy.

Diab SG, Hilsenbeck SG, de Moor C, Clark GM, Osborne CK, Ravdin PM, Elledge RM.

J Clin Oncol. 1998 May;16(5):1655-60.

PMID:
9586875
50.

Supplemental Content

Loading ...
Support Center